Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: A phase III metastatic castration resistant prostate cancer trial

International Journal of Cancer

Volumn 136, Issue 8, 2015, Pages 1856-1862

  Goldkorn, Amir ^a   Ely, Benjamin ^b   Tangen, Catherine M ^b   Tai, Yu Chong ^c   Xu, Tong ^a   Li, Hongli ^b   Twardowski, Przemyslaw ^d   Van Veldhuizen, Peter J ^e   Agarwal, Neeraj ^f   Carducci, Michael A ^g   Monk, J Paul ^h   Garzotto, Mark ⁱ   Mack, Philip C ^j   Lara, Primo ^j   Higano, Celestia S ^k   Hussain, Maha ^l   Vogelzang, Nicholas J ^m   Thompson, Ian M ⁿ   Cote, Richard J ^o   Quinn, David I ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^f UNIVERSITY OF UTAH   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ PORTLAND VA MEDICAL CENTER   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^m Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

ⁿ UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^o UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Biomarker; Circulating tumor cells; Prognosis; Prostate cancer; Telomerase activity

Indexed keywords

TELOMERASE; TUMOR MARKER;

AGED; ARTICLE; BLACK PERSON; BLOOD SAMPLING; CANCER PROGNOSIS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CAUCASIAN; CIRCULATING TUMOR CELL; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; ENZYME ACTIVITY; ENZYME ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; BLOOD; CLINICAL TRIAL; DISEASE COURSE; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TUMOR EMBOLISM;

AGED; BIOMARKERS, TUMOR; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TELOMERASE;

EID: 84922661468     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29212     Document Type: Article

References (28)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Kelly WK, Halabi S, Carducci M, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 2012;30:1534-40.
3. Fizazi KS, Higano CS, Nelson JB, et al. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2013;31:1740-48.
4. Makarov DV, Loeb S, Getzenberg RG, et al. Biomarkers for prostate cancer. Annu Rev Med 2009;60:139-51.
5. Danila DC, Fleisher M, Scher HI. Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res 2011;17:3903-12.
6. Shaffer DR, Leversha MA, Danila DC, et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 2007;13:2023-29.
7. Goodman OB, Jr, Symanowski JT, Loudyi A, et al. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer. Clin Genitourin Cancer 2011;9:31-38.
8. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14:6302-9.
9. Erratum in: Clin Cancer Res 2009;15:1506.
10. Scher HI, Jia X, de Bono JS, et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 2009;10:233-39.
11. Scher HI, Heller G, Molina A, et al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebocontrolled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. J Clin Oncol 2011;29(Suppl):LBA4517.
12. Goldkorn A, Ely B, Quinn DI, et al. Circulating tumor cell (CTC) counts are prognostic of overall survival (OS) in SWOG S0421-docetaxel with or without atrasentan for metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 2014;32:1136-42.
13. Danila DC, Anand A, Sung CC, et al. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castrationresistant prostate cancer patients treated with abiraterone acetate. Eur Urol 2011;60:897-904.
14. Jiang Y, Palma JF, Agus DB, et al. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem 2010;56:1492-95.
15. de Lange T, Lundblad V, eds. Telomeres, 2nd edn. New York: Cold Spring Harbor Laboratory Press, 2005.
16. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997;33:787-91.
17. Meeker AK. Telomeres and telomerase in prostatic intraepithelial neoplasia and prostate cancer biology. Urol Oncol 2006;24:122-30.
18. Sanchini MA, Gunelli R, Nanni O, et al. Relevance of urine telomerase in the diagnosis of bladder cancer. JAMA 2005;294:2052-6.
19. Clark GM, Osborne CK, Levitt D, et al. Telomerase activity and survival of patients with node positive breast cancer. J Natl Cancer Inst 1997;89:1874-81.
20. Tatsumoto N, Hiyama E, Murakami Y, et al. High telomerase activity is an independent prognostic indicator of poor outcome in colorectal cancer. Clin Cancer Res 2000;6:2696-701.
21. Zheng S, Lin H, Liu JQ, et al. Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. J Chromatogr A 2007;1162:154-61.
22. Lin HK, Zheng S, Williams AJ, et al. Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res 2010;16:OF1-8.
23. Xu T, Lu B, Tai YC, et al. A cancer detection platform which measures telomerase activity from live circulating tumor cells captured on a microfilter. Cancer Res 2010;70:6420-6.
24. Quinn DI, Tangen CM, Hussain M, et al. Docetaxel and atrasentan compared to docetaxel and placebo for men with advanced castration resistant prostate cancer: SWOG S0421. Lancet Oncol 2013;14:893-900.
25. Lara PM, Jr, Ely B, Quinn DI, et al. Serum biomarkers of bone metabolism in castration resistant prostate cancer patients with skeletal metastases. J Natl Cancer Inst 2014;106.
26. Goldkorn A, Blackburn EH. Assembly of mutant template telomerase RNA into catalytically active telomerase ribonucleoprotein that can act on telomeres is required for apoptosis and cell cycle arrest in human cancer cells. Cancer Res 2006;66:5763-71.
27. Xu T, Xu Y, Liao CP, et al. Reprogramming murine telomerase rapidly inhibits the growth of mouse cancer cells in vitro and in vivo. Mol Cancer Therap 2010;9:438-49.
28. Glass TR, Tangen CM, Crawford ED, et al. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol 2003;169:164-9.